313 related articles for article (PubMed ID: 33316691)
1. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.
Zhao R; Fu L; Yuan Z; Liu Y; Zhang K; Chen Y; Wang L; Sun D; Chen L; Liu B; Zhang L
Eur J Med Chem; 2021 Jan; 210():113088. PubMed ID: 33316691
[TBL] [Abstract][Full Text] [Related]
2. Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer.
Qin Z; Wang P; Li X; Zhang S; Tian M; Dai Y; Fu L
Mol Biosyst; 2016 Jun; 12(7):2108-18. PubMed ID: 27113542
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
[TBL] [Abstract][Full Text] [Related]
4. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
5. Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines.
Badran A; Atia-Tul-Wahab ; Fayyaz S; Baydoun E; Choudhary MI
Med Chem; 2019; 15(7):738-742. PubMed ID: 30398120
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer.
Zhang J; Zou L; Shi D; Liu J; Zhang J; Zhao R; Wang G; Zhang L; Ouyang L; Liu B
J Med Chem; 2021 Oct; 64(19):14192-14216. PubMed ID: 34605238
[TBL] [Abstract][Full Text] [Related]
8. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
9. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
[TBL] [Abstract][Full Text] [Related]
10. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
[TBL] [Abstract][Full Text] [Related]
12. Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.
Shen LW; Jiang XX; Li ZQ; Li J; Wang M; Jia GF; Ding X; Lei L; Gong QH; Gao N
Acta Pharmacol Sin; 2022 Jan; 43(1):177-193. PubMed ID: 34294886
[TBL] [Abstract][Full Text] [Related]
13. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
15. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer.
Yao D; Zhou Y; Zhu L; Ouyang L; Zhang J; Jiang Y; Zhao Y; Sun D; Yang S; Yu Y; Wang J
Eur J Med Chem; 2017 Nov; 140():155-171. PubMed ID: 28923383
[TBL] [Abstract][Full Text] [Related]
18. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.
Matossian MD; Burks HE; Elliott S; Hoang VT; Zuercher WJ; Wells C; Drewry DH; Kapadia N; Chang T; Yan T; Windsor GO; Nguyen K; Fang F; Nephew KP; Buechlein A; Rusch DB; Sabol RA; Ucar DA; Zabaleta J; Miele L; Bunnell BA; Collins-Burow BM; Burow ME
Anticancer Drugs; 2020 Sep; 31(8):759-775. PubMed ID: 32796402
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer.
Yao D; Huang J; Wang J; He Z; Zhang J
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1524-1538. PubMed ID: 32752894
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells.
Zhang J; Zou L; Tang P; Pan D; He Z; Yao D
Eur J Med Chem; 2020 May; 194():112220. PubMed ID: 32222676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]